Interventional, randomized, double-blind, placebo-controlled study of the efficacy and safety of initial administration of 25 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patients with Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Vortioxetine (Primary) ; Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Lundbeck A/S
- 28 Aug 2019 Status changed from recruiting to completed.
- 06 May 2019 Planned End Date changed from 27 May 2019 to 1 Aug 2019.
- 06 May 2019 Planned primary completion date changed from 27 May 2019 to 1 Aug 2019.